Results 171 to 180 of about 81,289 (311)

Management and treatment of contact lens-related Pseudomonas keratitis

open access: yesClinical Ophthalmology, 2012
Mark DP WillcoxSchool of Optometry and Vision Science, University of New South Wales, Sydney, AustraliaAbstract: Pubmed and Medline were searched for articles referring to Pseudomonas keratitis between the years 2007 and 2012 to obtain an overview of the
Willcox MD
doaj  

Intelligent peptide‐based nanomaterials for targeted antibacterial therapy: Design, properties and applications

open access: yesResponsive Materials, Volume 3, Issue 3, August 2025.
This review comprehensively discusses intelligent peptide‐based nanomaterials from the design, mechanisms, properties, and applications, taking stimuli responsiveness as a starting point. Abstract Bacterial infections pose a major threat to human health as well as livestock production. Traditional antibiotics face significant limitations in the complex
Chenlong Zhou   +8 more
wiley   +1 more source

Can the choice of artificial tears harm patients? A narrative review with an overview of the Nordic market

open access: yesActa Ophthalmologica, Volume 103, Issue 5, Page 586-608, August 2025.
Abstract Purpose To provide an overview of artificial tears marketed in the following Nordic countries: Denmark, Finland, Norway, Iceland and Sweden. Furthermore, this review aimed to highlight the different preservatives and other constituents found in artificial tears in the Nordic market, focussing on adverse effects.
K. N. Mikha   +9 more
wiley   +1 more source

Calcareous Keratitis [PDF]

open access: bronze, 1930
Adrian Caddy
openalex   +1 more source

Acanthamoebic keratitis [PDF]

open access: yesAustralian and New Zealand Journal of Ophthalmology, 1991
openaire   +2 more sources

Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia–Pacific Region

open access: yesClinical &Experimental Allergy, Volume 55, Issue 8, Page 691-700, August 2025.
Asthma prevalence is increasing in the Asia–Pacific region, and this population is frequently underrepresented in phase 3 clinical studies. We demonstrate Dupilumab's efficacy and safety among patients with uncontrolled moderate‐to‐severe type 2 asthma.
Qingling Zhang   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy